



NEONATAL MEDICATION PROTOCOLS

CARBAMAZEPINE
Created by: NCCU
Date for review: Sep 2016

NCCU Clinical Guidelines
KEMH/PMH
Perth, Western Australia

DRUG:	CARBAMAZEPINE
PRESENTATION:	Oral Liquid: 20mg/mL
ACTION & INDICATION:	An anticonvulsant to treat a range of neonatal seizures
DOSE:	2mg/kg/dose every 8 hours, increasing over two weeks to 5mg/kg/dose every 8 hours Increase dose slowly to allow for enzyme induction on initiation of therapy.
ADMINISTRATION:	Oral
ADVERSE EFFECTS:	May cause: Blood dyscrasias Cardiovascular, renal, hepatic disturbances Drowsiness
COMMENTS:	Drug interactions include: Phenytoin - may alter level of both drugs Erythromycin – increases level of carbamazepine
DRUG LEVELS:	Sampling time: Just before next dose Therapeutic range: 5-10mg/L Time to reach steady rate: 2-4 weeks
REFERENCES:	Paediatric Pharmacopoeia 13 th Ed Royal Children's Hospital, Melbourne
DATE:	September 2013